Ionic® Purification System for clinical and oncology researchers launched in Europe
GC biotech is the first to distribute Purigen Biosystems’ instrument in the Benelux
Waddinxveen (NL), April 14th, 2022
GC biotech announced a new distribution agreement with Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples. Under the terms of the deal, GC biotech has received exclusive rights to distribute, service, and support Purigen’s automated Ionic® Purification System and microfluidic kits in the Netherlands, Belgium, and Luxembourg. Clinical and oncology researchers in these countries are now able to purchase and use the automated system, which received a CE (Conformité Européene) marking in May 2021, to extract higher yields of purified DNA and RNA from challenging samples in one hour with minimal hands-on time.
“GC biotech is committed to working with the most advanced and innovative suppliers in the US and the European Union to accelerate discoveries and simplify workflows in research and clinical laboratories,” said Glenn Nohar, Owner and CEO of GC biotech. “Purigen’s Ionic Purification System and kits are a strong addition to our overall product portfolio and will enable our customers to rapidly generate higher yields of DNA or RNA from their most precious biological samples.”
Launched in the US market in 2019, the small benchtop Ionic Purification System enables the automated extraction of nucleic acids with dramatically increased yield and quality from a wide range of sample types, including cultured or sorted cells and formalin-fixed, paraffin-embedded (FFPE) tissues. Biological samples are gently lysed and then loaded into the Ionic® Fluidics Chip. The system applies an electrical field to the chip and nucleic acids are isolated in their native form using the company’s core isotachophoresis (ITP) technology. Since nucleic acids are not bound or stripped from fixed surfaces, sample loss and fragmentation are minimized while purification-induced bias is eliminated. The simplified workflow requires minimal hands-on time and ensures that sufficient amounts of nucleic acid are available for all downstream analysis techniques, such as next-generation sequencing and qPCR.
“GC biotech is well known in the Netherlands, Belgium, and Luxembourg for its expertise and technical capabilities,” said Aziz Mustafa, PhD, Senior Director of European Sales and Business Development for Purigen Biosystems. “This agreement is a significant step towards our goal of making the Ionic system readily available across the entire European Union.”
About Purigen Biosystems
Purigen Biosystems is redefining nucleic acid sample preparation with an innovative platform based on the highly efficient isotachophoresis technology invented by Juan Santiago, PhD, and his team at Stanford University. Purigen’s automated benchtop instrument and accompanying microfluidic chip purify nucleic acid samples from a wide variety of sources, including minute or otherwise challenging cancer samples. The purified nucleic acids are immediately compatible with a wide range of downstream detection methods, including next-generation sequencing, PCR, and other genomic tests. For more information, visit www.purigenbio.com or contact firstname.lastname@example.org.
About GC biotech
GC biotech sources the latest developments in automation for life science research from around the world. We aim to help you take research to a higher level. As a specialist in life science automation, GC biotech is committed to providing the best application and technical support to its customers. In addition, and unlike many other suppliers, our product advice is completely independent and tailored to your requirements. You will meet our service engineers, application specialists and sales reps in the Benelux, Germany, the United Kingdom, Scandinavia and the rest of Europe. For more information, visit www.gcbiotech.com or contact email@example.com.